The Top 2 IPO Stocks to Avoid This September

Two of the hottest IPO stocks investors are talking about in September are coronavirus vaccine developer CureVac (NASDAQ: CVAC) and cloud-data giant Snowflake (NYSE: SNOW). In a short amount of time, these two stocks have turned initial investors' capital into a fortune, with CureVac more than tripling from its IPO price of $16 in August and Snowflake stock more than doubling its $120 IPO price on the first day of trading. 

However, both companies now share a common problem: extreme overvaluation. Investors could get more bang for their buck at these price levels by buying just about anything else. Let's look at why, at these prices, neither CureVac nor Snowflake is a stock to put into your investment portfolio for the long term. 

Image source: Getty Images.

Continue reading

Source Fool.com